- ZLAB
- ZLAB
Key Points
-
Interested in Zai Lab Limited Unsponsored ADR? Here are five stocks we like better.
-
Zai Lab reported $108.2 million in Q3 revenue and expects to return to year-over-year product revenue growth in 2027. Net product revenue rose 2% sequentially, and the China commercial business remained profitable.
-
Its lead cancer candidate, zoci, showed an 81.8% confirmed response rate in a small Phase 1 combination study for first-line small cell lung cancer. Zai Lab aims to have three registrational studies underway by year-end and sees potential U.S. filings in 2027, subject to trial results and regulatory decisions.
-
An approximately $250 million October equity financing strengthened funding for development plans. The company is also counting on commercial drivers including VYVGART and KarXT growth and a ZEJULA return to growth to support its 2027 outlook.
Zai Lab (NASDAQ:ZLAB) reported $108.2 million in third-quarter revenue and said it expects to return to year-over-year product revenue growth in 2027, while advancing its lead cancer drug candidate toward potential U.S. regulatory submissions next year.
Founder, CEO and Chairperson Samantha Du said the company expects three registrational studies of zoci to be underway by year-end across small cell lung cancer and neuroendocrine carcinomas. Zai Lab anticipates two registrational results and its first potential U.S. biologics license application in 2027, with a possible U.S. launch as early as 2028.
→ Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
The timing depends on clinical results and regulatory decisions. Zai Lab also said an approximately $250 million equity financing completed in October strengthened its ability to fund its development plans.
Zoci Studies Target Multiple Cancer Settings
President and Head of Global Research and Development Rafael Amado reviewed first-line small cell lung cancer data presented at the ESMO conference from a global Phase 1 study of zoci, a DLL3-targeting antibody-drug conjugate, combined with atezolizumab.
→ Washington Made a $2 Billion Quantum Bet, But Can Either ETF Match It?
Among 33 efficacy-evaluable, previously untreated patients receiving the selected zoci dose, the combination produced a confirmed objective response rate of 81.8%. Estimated six-month progression-free survival was 81.9%, Amado said. Among the first 15 patients, with a median follow-up of 10 months, median progression-free survival and duration of response had not been reached; 10 had not progressed at the data cutoff.
